Design of Cell-Permeable Inhibitors of Eukaryotic Translation Initiation Factor 4E (eIF4E) for Inhibiting Aberrant Cap-Dependent Translation in Cancer

Overview

Journal bioRxiv

Date 2023 Jun 9

PMID 37292917

Authors

Emilio L Cardenas

Rachel L ORourke

Arya Menon

Jennifer Meagher

Jeanne Stuckey

Amanda L Garner

Affiliations

Soon will be listed here.

Abstract

Eukaryotic translation initiation factor 4E (eIF4E) is an RNA-binding protein that binds to the m GpppX-cap at the 5' terminus of coding mRNAs to initiate cap-dependent translation. While all cells require cap-dependent translation, cancer cells become addicted to enhanced translational capacity, driving the production of oncogenic proteins involved in proliferation, evasion of apoptosis, metastasis, and angiogenesis among other cancerous phenotypes. eIF4E is the rate-limiting translation factor and its activation has been shown to drive cancer initiation, progression, metastasis, and drug resistance. These findings have established eIF4E as a translational oncogene and promising, albeit challenging, anti-cancer therapeutic target. Although significant effort has been put forth towards inhibiting eIF4E, the design of cell-permeable, cap-competitive inhibitors remains a challenge. Herein, we describe our work towards solving this long-standing challenge. By employing an acyclic nucleoside phosphonate prodrug strategy, we report the synthesis of cell-permeable inhibitors of eIF4E binding to capped mRNA to inhibit cap-dependent translation.

References

Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler L, Sonenberg N . eIF4E--from translation to transformation. Oncogene. 2004; 23(18):3172-9. DOI: 10.1038/sj.onc.1207549. View

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

Li S, Jia Y, Jacobson B, McCauley J, Kratzke R, Bitterman P . Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation. Mol Pharm. 2013; 10(2):523-31. PMC: 5920544. DOI: 10.1021/mp300699d. View

Chiodi D, Ishihara Y . "Magic Chloro": Profound Effects of the Chlorine Atom in Drug Discovery. J Med Chem. 2023; 66(8):5305-5331. DOI: 10.1021/acs.jmedchem.2c02015. View

Pelletier J, Graff J, Ruggero D, Sonenberg N . Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015; 75(2):250-63. PMC: 4299928. DOI: 10.1158/0008-5472.CAN-14-2789. View

Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I . Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015; 14(4):261-78. DOI: 10.1038/nrd4505. View

Robichaud N, Sonenberg N, Ruggero D, Schneider R . Translational Control in Cancer. Cold Spring Harb Perspect Biol. 2018; 11(7). PMC: 6601465. DOI: 10.1101/cshperspect.a032896. View

Truitt M, Conn C, Shi Z, Pang X, Tokuyasu T, Coady A . Differential Requirements for eIF4E Dose in Normal Development and Cancer. Cell. 2015; 162(1):59-71. PMC: 4491046. DOI: 10.1016/j.cell.2015.05.049. View

Graff J, Konicek B, Vincent T, Lynch R, Monteith D, Weir S . Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 2007; 117(9):2638-48. PMC: 1957541. DOI: 10.1172/JCI32044. View

10.

Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R . Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene. 2012; 32(23):2848-57. DOI: 10.1038/onc.2012.306. View

11.

McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, Read R . Phaser crystallographic software. J Appl Crystallogr. 2009; 40(Pt 4):658-674. PMC: 2483472. DOI: 10.1107/S0021889807021206. View

12.

Gallagher E, Song J, Menon A, Mishra L, Chmiel A, Garner A . Consideration of Binding Kinetics in the Design of Stapled Peptide Mimics of the Disordered Proteins Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 and Eukaryotic Translation Initiation Factor 4G. J Med Chem. 2019; 62(10):4967-4978. PMC: 6679956. DOI: 10.1021/acs.jmedchem.9b00068. View

13.

Dhanasekaran R, Deutzmann A, Mahauad-Fernandez W, Hansen A, Gouw A, Felsher D . The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2021; 19(1):23-36. PMC: 9083341. DOI: 10.1038/s41571-021-00549-2. View

14.

Groaz E, De Jonghe S . Overview of Biologically Active Nucleoside Phosphonates. Front Chem. 2021; 8:616863. PMC: 7821050. DOI: 10.3389/fchem.2020.616863. View

15.

Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites E . Cancer gene mutation frequencies for the U.S. population. Nat Commun. 2021; 12(1):5961. PMC: 8514428. DOI: 10.1038/s41467-021-26213-y. View

16.

Chen X, Kopecky D, Mihalic J, Jeffries S, Min X, Heath J . Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction. J Med Chem. 2012; 55(8):3837-51. DOI: 10.1021/jm300037x. View

17.

Khan N, Shah P, Ban D, Trigo-Mourino P, Carneiro M, DeLeeuw L . Solution structure and functional investigation of human guanylate kinase reveals allosteric networking and a crucial role for the enzyme in cancer. J Biol Chem. 2019; 294(31):11920-11933. PMC: 6682748. DOI: 10.1074/jbc.RA119.009251. View

18.

Visco C, Perrera C, Thieffine S, Sirtori F, DAlessio R, Magnaghi P . Development of biochemical assays for the identification of eIF4E-specific inhibitors. J Biomol Screen. 2012; 17(5):581-92. DOI: 10.1177/1087057112438554. View

19.

Pradere U, Roy V, Montagu A, Sari O, Hamada M, Balzarini J . Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides. Eur J Med Chem. 2012; 57:126-33. DOI: 10.1016/j.ejmech.2012.08.042. View

20.

Golojuch S, Kopcial M, Strzelecka D, Kasprzyk R, Baran N, Sikorski P . Exploring tryptamine conjugates as pronucleotides of phosphate-modified 7-methylguanine nucleotides targeting cap-dependent translation. Bioorg Med Chem. 2020; 28(13):115523. DOI: 10.1016/j.bmc.2020.115523. View